Home › Funds › ARMISTICE CAPITAL, LLC › AGIO

ARMISTICE CAPITAL, LLC position in AGIO

AGIOS PHARMACEUTICALS INC · Health Care

ARMISTICE CAPITAL, LLC reported holding 2,400,000 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$89.1M, representing 1.17% of its reported portfolio and ranking #8 among its reported holdings. ARMISTICE CAPITAL, LLC has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)2.40M sh
Reported value held$89.06M
Portfolio Weight1.17%
First reportedQ3 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How ARMISTICE CAPITAL, LLC's AGIO position evolved

ARMISTICE CAPITAL, LLC first disclosed a stake in AGIO in Q3 2023 at 3,324,000 shares (US$82.3M). The position peaked in Q3 2024 at 2,207,070 shares, worth US$98.1M. Across 12 filings, ARMISTICE CAPITAL, LLC increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,400,000 shares valued at US$89.1M — a reduction of -316,000 shares quarter over quarter.. Notable position changes include a 43% trim in Q2 2025 (shares rose 21% over the following quarter), a 42% increase in Q3 2025 (shares fell 32% over the following quarter), a 80% increase in Q4 2025 (shares rose 24% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.32M $82.27M New
Q4 2023 3.52M $78.48M Add
Q1 2024 2.96M $86.67M Reduce
Q2 2024 2.08M $89.65M Reduce
Q3 2024 2.21M $98.06M Add
Q4 2024 2.26M $74.41M Add
Q1 2025 2.05M $60.01M Reduce
Q2 2025 1.17M $38.85M Reduce
Q3 2025 1.66M $66.79M Add
Q4 2025 3.00M $81.66M Add
Q1 2026 2.72M $91.88M Reduce
Q2 2026 2.40M $89.06M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About AGIO and 13F data

AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 30 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$219.6M), Lynx1 Capital Management LP (US$126.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding AGIO

All AGIO fund holders →

FAQ

How long has ARMISTICE CAPITAL, LLC held AGIO?

ARMISTICE CAPITAL, LLC has disclosed AGIO holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is ARMISTICE CAPITAL, LLC's current position in AGIO?

As of Q2 2026, ARMISTICE CAPITAL, LLC holds 2.40M shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $89.06M, representing 1.17% of its reported portfolio and ranking #8.

Has ARMISTICE CAPITAL, LLC been buying or selling AGIO?

In the latest 13F filing (Q2 2026), ARMISTICE CAPITAL, LLC reduced its position in AGIO. The position peaked in Q3 2024 at 2.21M shares.

Which other funds hold AGIO?

Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Lynx1 Capital Management LP, among 30 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.